International Journal of Infectious Diseases · 2023 · 18 citations · 15 references
Life SciencesInfectious DiseasesMicrobiologyBacteriologyClinical EpidemiologyMedical MicrobiologyBacterial Disease EpidemiologyBacterial EpidemiologyBacterial InfectionsClinical BacteriologyMedical BacteriologyNosocomial Infection EpidemiologyCommunity-acquired Bacterial InfectionsEpidemiology Of Bacterial InfectionsEscherichia ColiExtended-spectrum Beta-lactamase Producing OrganismsExtended-spectrum Beta-lactamase ProductionExtended-spectrum Beta-lactamase-producing OrganismsInfection Risk FactorsRecurrent Bloodstream Infection
OBJECTIVES: This population-based study aimed to investigate the risk factors and effect of extended-spectrum beta-lactamase (ESBL) production on clinical outcomes in Escherichia coli bloodstream infection (BSI) patients. METHODS: The study population was defined as patients aged ≥15 years with E. coli BSI in Queensland, Australia, from 2000 to 2019. Outcomes were defined as 30-day case fatality, hospital length of stay (LOS), and recurrent E. coli BSI. RESULTS: A total of 27,796 E. coli BSIs were identified, of which 1112 (4.0%) were ESBL-producers. Patients with ESBL-Ec BSI were more frequently older, male, with comorbidity, recurrent E. coli BSI, and less likely with community-associated community-onset infections as compared to non-ESBL-Ec BSI patients. The standardized mortality rate of ESBL-Ec BSI increased 8-fold from 2000 to 2019 (1 to 8 per million residents) and case fatality was 12.8% (n = 142) at 30 days from positive blood culture. Patients with ESBL-Ec BSI were not at higher risk of 30-day case fatality (adjusted hazard ratio [HR] = 0.98, 95% CI: 0.83-1.17), but had higher risk of recurring episodes (adjusted subdistribution HR = 1.58, 95% CI: 1.29-1.92) and observed 14% longer LOS (adjusted incidence rate ratio = 1.14, 95% CI: 1.10-1.18) than non-ESBL-Ec BSI patients. CONCLUSION: In this large patient cohort, ESBL-Ec BSI did not increase case fatality risk but observed higher hospital LOS and recurrent E. coli BSI than non-ESBL-Ec BSI. Clinical resources are warranted to account for the higher morbidity risk associated with ESBL production and incidence.
15
Erik von Elm, Douglas G. Altman, Matthias Egger et al. · The Lancet · 2007 · 18.7K citations · Full text
Public Health, Public Health Practice, Epidemiologic Methods +10
Lapo Mughini‐Gras, Alejandro Dorado-García, Engeline van Duijkeren et al. · The Lancet Planetary Health · 2019 · 285 citations · Full text
Jesús Rodríguez‐Baño, Encarnación Picón, Paloma Gijón et al. · Journal of Clinical Microbiology · 2010 · 156 citations · Full text